stock price

BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.

The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.

The GenomeWeb index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index.

The UK Competition and Markets Authority said blocking the deal could prevent a "substantial lessening of competition" in the NGS market.

Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares.

Though Meehan was cautious on Waters in the near term, he provided a favorable outlook on Thermo Fisher Scientific.

Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.

The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.